Date of submission of the HTAC Recommendation: 19 January 2026
Date of notification to HTAC on the SOH decision: 07 May 2026
The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on (1) Atezolizumab [60 mg/mL, 20 mL vial for intravenous (IV) infusion] + Bevacizumab [25 mg/mL, 4 mL or 16 mL vial for IV infusion] and (2) Lenvatinib [4 mg or 10 mg capsule] for adults diagnosed with advanced or unresectable hepatocellular carcinoma (uHCC) through Department of Health (DOH) Department Circular No. 2026-0218 “Inclusion of Atezolizumab + Bevacizumab and Lenvatinib in the Philippine National Drug Formulary for Adults Diagnosed with Advanced or Unresectable Hepatocellular Carcinoma” published on 05 May 2026.
As a final recommendation, the HTA Council recommends the following for government financing:
- Atezolizumab [60 mg/mL, 20 mL vial for intravenous (IV) infusion] + Bevacizumab [25 mg/mL, 4 mL or 16 mL vial for IV infusion] as preferred first-line treatment for adults diagnosed with advanced or unresectable HCC; and,
- Lenvatinib [4 mg/10 mg capsule] as first-line treatment for adults diagnosed with advanced or unresectable HCC who are not candidates for immunotherapy and/or anti-VEGF.
For further details, please refer to the documents below: